Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frespaciguat in Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
NCT05612035Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension (PH) comparing Frespaciguat with Placebo (2 arms). Primary endpoint: 6-minute Walk Distance at 24 weeks. Started Mar 2023; status: active, not recruiting.
02
Drugs
frespaciguat
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT05612035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05612035.